Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,004 public trials 571 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

NCT05243342

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Alfred Hospital Melbourne, Victoria, Australia
  • Odense Universitetshospital Odense C, Region Syddanmark, Denmark
  • Sygehus Lillebælt, Vejle Vejle, Region Syddanmark, Denmark
View Trial Details
Completed

Myeloma-Developing Regimens Using Genomics (MyDRUG)

NCT03732703

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Mayo Clinic - Arizona Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
View all 16 locations
View Trial Details
Completed

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients

NCT03792763

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • IIIrd Medical Department, Private Medical University Hospital Salzburg Salzburg, State of Salzburg, Austria
  • Medizinische Universitaet Graz, Univ.-Klinik f. Innere Medizin, Onkologie Graz, Austria
  • Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V Hämatologie und Onkologie Innsbruck, Austria
  • LKH Hochsteiermark, Standort Leoben, Abteilung für Innere Medizin und Hämatologie und internistische Onkologie Leoben, Austria
View Trial Details
Completed

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

NCT02874742

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Birmingham, Alabama, United States
  • Duarte, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
View all 36 locations
View Trial Details
Completed

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT03357952

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • ZNA Stuivenberg Antwerp, Belgium
  • Algemeen Ziekenhuis Klina Brasschaat, Belgium
  • AZ St.-Jan Brugge-Oostende AV Bruges, Belgium
  • UZBrussel Brussels, Belgium
View all 13 locations
View Trial Details

Related conditions